Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E141.24 EPS (ttm)2.95 Insider Own1.10% Shs Outstand101.67M Perf Week-0.84%
Market Cap42.36B Forward P/E35.36 EPS next Y11.78 Insider Trans-22.15% Shs Float74.70M Perf Month2.04%
Income334.70M PEG7.68 EPS next Q2.78 Inst Own73.00% Short Float5.87% Perf Quarter7.47%
Sales2.63B P/S16.12 EPS this Y-43.60% Inst Trans0.39% Short Ratio5.49 Perf Half Y31.76%
Book/sh25.32 P/B16.46 EPS next Y17.80% ROA10.00% Target Price431.91 Perf Year42.22%
Cash/sh10.25 P/C40.64 EPS next 5Y18.38% ROE14.70% 52W Range269.50 - 437.64 Perf YTD1.56%
Dividend- P/FCF78.86 EPS past 5Y42.20% ROI19.20% 52W High-4.79% Beta0.89
Dividend %- Quick Ratio5.10 Sales past 5Y54.60% Gross Margin87.70% 52W Low54.60% ATR13.33
Employees2714 Current Ratio5.40 Sales Q/Q21.60% Oper. Margin30.60% RSI (14)52.79 Volatility2.95% 3.18%
OptionableYes Debt/Eq0.22 EPS Q/Q-44.00% Profit Margin12.70% Rel Volume1.29 Prev Close414.64
ShortableYes LT Debt/Eq0.22 EarningsFeb 10 BMO Payout0.00% Avg Volume798.24K Price416.66
Recom1.90 SMA201.33% SMA500.87% SMA20018.78% Volume1,031,966 Change0.49%
Nov-20-14Reiterated Brean Capital Buy $390 → $450
Nov-19-14Reiterated ROTH Capital Buy $422 → $461
Nov-11-14Reiterated Argus Buy $375 → $430
Nov-05-14Reiterated RBC Capital Mkts Outperform $373 → $410
Oct-24-14Reiterated Canaccord Genuity Buy $350 → $460
Sep-02-14Reiterated Brean Capital Buy $380 → $390
Aug-06-14Reiterated RBC Capital Mkts Outperform $349 → $373
Jul-21-14Initiated Argus Buy $375
Apr-16-14Initiated Canaccord Genuity Buy $350
Feb-13-14Downgrade Oppenheimer Outperform → Perform $310 → $325
Sep-30-13Reiterated Oppenheimer Outperform $300 → $310
Aug-22-13Initiated Oppenheimer Outperform $300
May-17-13Initiated UBS Neutral $290
May-06-13Reiterated RBC Capital Mkts Outperform $270 → $286
May-06-13Reiterated Barclays Overweight $275 → $305
May-02-13Reiterated Barclays Overweight $194 → $275
Feb-28-13Initiated Barclays Overweight $194
Dec-21-12Reiterated RBC Capital Mkts Outperform $171 → $190
Feb-14-12Reiterated RBC Capital Mkts Outperform $83 → $130
Jan-10-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
Jan-30-15 12:15PM  Upside play in biotech space CNBC
12:15PM  Obama unveils precision medicine initiative CNBC
07:03AM  White House targets precision medicine CNBC
06:00AM  Obama's $215 Million DNA Sequencing Project Is A Great Idea at Forbes
06:00AM  Obama seeks $215 million for 'precision medicine' at CNBC
Jan-29-15 02:41PM  Vertex head of research, Broad co-founder David Altshuler to meet with Obama Friday at American City Business Journals
Jan-28-15 05:06PM  Drugmakers get mysterious invites to White House at CNBC
04:55PM  Regeneron, Vertex execs heads to White House CNBC
Jan-27-15 06:50PM  Regeneron/Sanofi's PCSK9 Drug Gets FDA Priority Review - Analyst Blog Zacks
04:45PM  Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Zacks
03:20PM  Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Zacks
Jan-26-15 05:22PM  Medivation CEO's Planned Sale Hits $10.8M in Stock at Barrons.com
06:53AM  Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune
02:46AM  Sanofi And Regeneron Leapfrog Amgen In New Cholesterol Drug Race at Forbes
01:00AM  Sanofi and Regeneron Gain Edge on Amgen in Cholesterol Drug Race at Bloomberg
01:00AM  Regeneron/Sanofi cholesterol drug gets FDA priority review Reuters
01:00AM  Regeneron and Sanofi Announce Praluent (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA PR Newswire
Jan-23-15 07:32AM  EYLEA┬« (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union PR Newswire
Jan-22-15 03:45PM  Ebola vaccine trials to begin in Liberia at CNBC
04:13AM  US investors double down on biotech bets at Financial Times
Jan-20-15 06:56PM  Lightning Round: I prefer this to Alibaba at CNBC
04:43PM  The 5 Biggest Biotech Stocks Benzinga
10:00AM  Benefits firms shouldn't play drug favorites: CEO at CNBC
09:55AM  Cramer's Stop Trading: Biotech hangover CNBC
07:41AM  Regeneron CEO: Choice, not price best for patients CNBC
Jan-14-15 02:48PM  New York drug developer's big money maker had nearly $1.74B in sales last year at American City Business Journals
Jan-13-15 01:32PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
10:32AM  Veteran Analyst's Top Health-Care Picks for 2015 at Barrons.com
Jan-12-15 01:10AM  Sanofi, Regeneron submit new cholesterol drug to EMA for review Reuters
01:00AM  Regeneron and Sanofi Announce Praluent (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA PR Newswire
Jan-09-15 04:41PM  A volatile end to a very volatile week... Yahoo Finance Contributors
03:42PM  Regeneron Jumps On Favorable Cholesterol Drug Report at Investor's Business Daily
01:58PM  Regeneron Can Generate 25% Upside for Investors at Barrons.com
11:52AM  Stocks Reverse Lower On Good News/Bad News Job Data at Investor's Business Daily
10:37AM  Sanofi, Regeneron cholesterol drug also effective in monthly doses Reuters
09:30AM  Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015 PR Newswire
08:58AM  Morning Movers: Starbucks Sinks on COO Leave; Tesla Tumbles at Barrons.com
07:56AM  Early movers: GPS, SBUX, SHOO, BHI & more at CNBC
01:20AM  Sanofi, Regeneron announce positive trials of cholesterol drug Reuters
01:00AM  Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia PR Newswire
Jan-08-15 03:43PM  Does 23andMe Deal Mean Medical Centers Are Sitting On Data Worth Millions? at Forbes
08:02AM  5 Potential Blockbuster Drugs Set To Launch In 2015 at Investor's Business Daily
Jan-06-15 11:28AM  UPDATE: Barclays Initiates Coverage On Regeneron Benzinga
09:55AM  Cramer's Stop Trading: Biotech underestimated CNBC
09:28AM  Cramer's Mad Dash: Don't leave biotech CNBC
Jan-05-15 06:10PM  Cramer's 10 lessons learned from 2014 at CNBC
11:21AM  Cramer Says Wells Fargo Is a Buy; Wait for a Regeneron Pullback at TheStreet
09:28AM  Cramer's Mad Dash: REGN & WFC CNBC
Dec-26-14 04:22PM  US STOCKS-Wall St ends at record in second straight weekly gain Reuters
04:16PM  Nasdaq, Russell 2000 Join New-High Party; GoPro Up Again at Investor's Business Daily
11:06AM  US STOCKS-Wall St hits records in broad, thinly traded rally Reuters
Dec-23-14 02:48PM  Fresh Milestones For Dow, S&P 500 But Biotechs Hit at Investor's Business Daily
01:22PM  Dow Crosses 18,000 But Medical-Related Groups Fall Hard at Investor's Business Daily
Dec-22-14 04:51PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
10:34AM  Stocks Struggle To Hold Gains; Alaska Air, Spirit Up at Investor's Business Daily
Dec-19-14 10:46AM  Cramer: Downside to Biotech as ImmunoGen Stock Cut in Half at TheStreet
09:24AM  Cramer's Mad Dash: Tale of two biotechs CNBC
Dec-18-14 08:10PM  Jim Cramer's 'Mad Money' Recap: 10 Reasons We'll Have a Santa Claus Rally at TheStreet
06:33PM  Cramer: Watch out Regeneron, here comes Isis at CNBC
06:13PM  Cramer's perfect recipe for a Santa Claus rally at CNBC
Dec-17-14 07:00PM  Cramer: Here's what the Fed did today CNBC
06:57PM  Lightning Round: Good stock with a good yield at CNBC
Dec-15-14 02:53PM  Stocks Hit By More Selling; S&P 500 Gives Up 50-Day Line at Investor's Business Daily
08:00AM  Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol PR Newswire
Dec-08-14 01:25PM  Stocks Fall To Session Lows: GoPro Gives Up More Ground at Investor's Business Daily
01:12PM  Midday movers: McDonald's, Sony, Celgene & more at CNBC
Dec-05-14 12:18PM  Cramer Says It May Finally Be Time to Buy Laggard Gilead Sciences at TheStreet
Dec-04-14 06:50PM  Lightning Round: Time to buy buy buy for 2015 at CNBC
09:40AM  Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015 at 24/7 Wall St.
08:15AM  Regeneron at 52-Week High on Eylea Priority Review Status Zacks
Dec-03-14 12:29PM  Jim Cramer on the Stock Market: You Have to Love Biotech at TheStreet
09:51AM  Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study Zacks
08:50AM  Stock Market News for December 03, 2014 Zacks
06:00AM  Jim Cramer's Top Stock Picks: REGN BMRN ISIS EOG BIIB CELG DECK ZOES at TheStreet
Dec-02-14 08:21PM  Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners at TheStreet
07:00PM  Cramer: One of the best stocks to own now CNBC
06:33PM  Cramer's heated love affair with biotech at CNBC
06:00PM  Cramer: Stocks you shouldn't chase CNBC
04:20PM  Regeneron/Bayer's Eylea to be Reviewed on a Priority Basis Zacks
11:27AM  Cramer: Cypress Semiconductor Merger With Spansion Is Fantastic at TheStreet
11:11AM  Jim Cramer's Five Best Stock Picks for the Biotech Sector at TheStreet
Dec-01-14 07:00AM  EYLEA┬« (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema PR Newswire
Nov-28-14 10:30AM  Insider Trading Alert - ALJ, REGN And PRSC Traded By Insiders at TheStreet
Nov-26-14 04:13PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Nov-25-14 11:07AM  Cramer: Workday, Netflix, Amazon Struggle as Momentum Lags at TheStreet
06:00AM  Jim Cramer's Top Stock Picks: CSCO LB REGN AAPL YHOO at TheStreet
Nov-24-14 08:22PM  Jim Cramer's 'Mad Money' Recap: Here's Where Money Managers Should Put Their Money at TheStreet
07:08PM  Cramer Remix: This industry isn't dead yet! at CNBC
06:40PM  Cramer: Not too late to buy Regeneron CNBC
Nov-21-14 04:23PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
10:24AM  UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts Benzinga
10:03AM  Fighting kids' cancer, one voucher at a time at CNBC
Nov-20-14 03:30PM  Regeneron & Sanofi Present Positive Data on PCSK9 Drug Zacks
03:27PM  Gilead to Buy Knight Therapeutics' Priority Review Voucher Zacks
12:31PM  Regeneron Shares Could Reach $450 at Barrons.com
11:44AM  Sanofi's Bullish Pipeline Forecast Underwhelms Street at Investor's Business Daily
08:31AM  Sanofi eyes more than $38 bln from new drugs after CEO exit Reuters
08:00AM  The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Zacks
01:47AM  Sanofi, Regeneron eczema drug gets FDA fast-track designation Reuters
01:30AM  Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis PR Newswire
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHLEIFER LEONARD SPresident & CEOJan 02Sale410.581,500615,8670Jan 05 04:56 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale414.0810,8224,481,21410,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise52.0325,0001,300,75035,711Jan 05 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 19Option Exercise30.633,26499,97610,711Dec 22 12:09 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise30.633,26499,97618,705Dec 19 02:11 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 17Option Exercise30.632,80085,7647,481Dec 18 04:22 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise49.076,818334,56010,556Dec 17 04:51 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 16Option Exercise30.633,26499,97664,436Dec 18 04:25 PM
STAHL NEILSVP Research and Development SDec 16Option Exercise30.633,26499,9766,541Dec 18 04:25 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise30.633,26499,976503,264Dec 18 04:23 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Sale410.006,8182,795,3804,681Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Option Exercise30.631,66851,0916,049Dec 17 04:51 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 15Sale410.761,668685,1444,681Dec 17 04:51 PM
POON CHRISTINE ADirectorNov 25Buy410.00400164,000655Nov 26 01:28 PM
GILMAN ALFRED GDirectorNov 24Option Exercise35.9640,0001,438,55040,000Nov 25 04:16 PM
GILMAN ALFRED GDirectorNov 24Sale408.4440,00016,337,5850Nov 25 04:16 PM
STAHL NEILSVP Research and Development SNov 24Sale409.782,200901,5233,277Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 21Sale415.163,1071,289,9025,477Nov 24 04:15 PM
STAHL NEILSVP Research and Development SNov 18Option Exercise115.2916,7571,931,91530,284Nov 20 04:14 PM
Terifay Robert JSVP CommercialNov 18Sale405.7922,3629,074,20020,029Nov 19 04:41 PM
Terifay Robert JSVP CommercialNov 17Option Exercise21.2548,7501,035,93868,779Nov 19 04:41 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 13Sale399.348,5753,424,33615,441Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Option Exercise177.825,000889,1009,000Nov 12 05:15 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 12Option Exercise21.2518,700397,37534,141Nov 14 04:32 PM
GOLDSTEIN JOSEPH LDirectorNov 12Sale398.315,0001,991,5504,000Nov 12 05:15 PM
SCHLEIFER LEONARD SPresident & CEONov 12Sale400.3242,32416,943,28542,087Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEONov 11Sale400.003,4931,397,20084,411Nov 12 05:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 31Sale400.113,4531,381,58087,904Nov 04 04:06 PM
SCHLEIFER LEONARD SPresident & CEOOct 28Sale404.0169,11227,921,80691,357Oct 29 04:27 PM
SCHLEIFER LEONARD SPresident & CEOOct 27Option Exercise19.40256,8084,982,219292,893Oct 29 04:27 PM
BROWN MICHAEL SDirectorOct 24Option Exercise57.115,000285,5505,000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 24Sale400.7026,78810,734,01863,102Oct 27 04:17 PM
BROWN MICHAEL SDirectorOct 24Sale399.005,0001,995,0000Oct 24 04:07 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrOct 23Option Exercise30.6360,0001,837,800123,102Oct 27 04:17 PM
VAGELOS P ROYChairman of the BoardSep 10Sale350.0710,3263,614,82392,947Sep 10 04:00 PM
VAGELOS P ROYChairman of the BoardSep 08Sale351.002702103,273Sep 10 04:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 27Option Exercise21.561,68136,2474,681Aug 28 02:39 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriAug 27Option Exercise314.315,7201,797,853505,720Aug 29 03:29 PM
Tessier-Lavigne MarcDirectorAug 27Option Exercise50.913,000152,7304,187Aug 27 05:02 PM
Tessier-Lavigne MarcDirectorAug 27Sale352.203,0001,056,6001,187Aug 27 05:02 PM
GOLDSTEIN JOSEPH LDirectorAug 27Sale350.312,000700,6204,000Aug 27 05:01 PM
Tessier-Lavigne MarcDirectorAug 26Option Exercise50.911,38770,6121,387Aug 27 05:02 PM
Aberman Michael SVP Strategy and Investor RelatAug 22Option Exercise24.003,00072,00018,600Aug 26 09:45 AM
Aberman Michael SVP Strategy and Investor RelatAug 19Sale350.003,6111,263,85015,600Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Option Exercise52.035,875305,6768,875Aug 18 04:04 PM
Aberman Michael SVP Strategy and Investor RelatAug 18Option Exercise52.038,750455,26324,350Aug 19 04:16 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 18Sale353.005,8752,073,8753,000Aug 18 04:04 PM
BROWN MICHAEL SDirectorAug 15Option Exercise33.423,000100,2603,000Aug 18 04:02 PM
BROWN MICHAEL SDirectorAug 15Sale349.203,0001,047,6000Aug 18 04:02 PM
GOLDSTEIN JOSEPH LDirectorAug 14Sale347.652,000695,3006,000Aug 14 04:14 PM
VAGELOS P ROYChairman of the BoardAug 13Sale340.018,0282,729,600248,540Aug 14 04:15 PM
VAGELOS P ROYChairman of the BoardAug 11Sale340.059,3723,186,967256,568Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 11Sale339.9611,6463,959,20413,527Aug 11 04:04 PM
VAGELOS P ROYChairman of the BoardAug 08Sale340.332,600884,858265,940Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 08Sale340.642,100715,34025,173Aug 08 04:49 PM
VAGELOS P ROYChairman of the BoardAug 07Option Exercise9.49270,3522,565,640411,191Aug 11 05:25 PM
STAHL NEILSVP Research and Development SAug 07Sale340.49741252,30427,273Aug 08 04:49 PM
STAHL NEILSVP Research and Development SAug 06Option Exercise21.2535,000743,75048,527Aug 08 04:49 PM
GOLDSTEIN JOSEPH LDirectorAug 06Sale331.202,000662,4008,000Aug 06 04:11 PM
REGENERON PHARMACEUTICALS INC10% OwnerAug 05Buy17.00588,2359,999,9951,809,098Aug 05 05:39 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM